PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34452397-5 2021 In the last few years, the discovery of the sodium taurocholate co-transporting polypeptide (NTCP) as a key cellular entry factor for HBV and HDV has allowed the development of new cell culture models susceptible to HBV and HDV infection. Taurocholic Acid 44-63 solute carrier family 10 member 1 Homo sapiens 93-97 34696350-5 2021 HBV infects human hepatocytes through transfer to the sodium taurocholate co-transporting polypeptide (NTCP). Taurocholic Acid 54-73 solute carrier family 10 member 1 Homo sapiens 103-107 33617845-11 2021 In marked contrast to the other E3S transporters, the bile acid transporter SLC10A1 (NTCP, Na+ taurocholate co-transporting polypeptide) showed a decrease in the accumulation of E3S in hyperosmolar buffer; the same was observed with taurocholic acid. Taurocholic Acid 95-107 solute carrier family 10 member 1 Homo sapiens 76-83 34079822-10 2021 The HBV/HDV-derived myr-preS1 peptide showed equipotent inhibition of the NTCP-mediated substrate transport of taurocholic acid (TC), dehydroepiandrosterone sulfate (DHEAS), and TLC with IC50 values of 182 nM, 167 nM, and 316 nM, respectively. Taurocholic Acid 111-127 solute carrier family 10 member 1 Homo sapiens 74-78 34079822-10 2021 The HBV/HDV-derived myr-preS1 peptide showed equipotent inhibition of the NTCP-mediated substrate transport of taurocholic acid (TC), dehydroepiandrosterone sulfate (DHEAS), and TLC with IC50 values of 182 nM, 167 nM, and 316 nM, respectively. Taurocholic Acid 129-131 solute carrier family 10 member 1 Homo sapiens 74-78 35635688-2 2022 We aimed to elucidate the relationships between HBV entry receptor sodium taurocholate co-transporting polypeptide (NTCP) and vaccine failure in children born to highly infectious mothers. Taurocholic Acid 67-86 solute carrier family 10 member 1 Homo sapiens 116-120 35580630-2 2022 Almost ten years ago the HBV receptor was identified as NTCP (sodium taurocholate co-transporting polypeptide), which interacts directly with the first 48 amino acid residues of the N-myristoylated N-terminal preS1 domain of the viral large (L) protein3. Taurocholic Acid 62-81 solute carrier family 10 member 1 Homo sapiens 56-60 35464922-10 2022 Analysis of HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP), showed that NTCP was correlated negatively to CSC markers in T samples, except for the CD44. Taurocholic Acid 26-45 solute carrier family 10 member 1 Homo sapiens 75-79 35464922-10 2022 Analysis of HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP), showed that NTCP was correlated negatively to CSC markers in T samples, except for the CD44. Taurocholic Acid 26-45 solute carrier family 10 member 1 Homo sapiens 94-98 34266968-12 2021 NTCP neutralizing antibody inhibited NTCP (less TCA uptake); it attenuated LF in both CCl4 and Ob/Ob HFD animal models with ameliorated metabolic profile. Taurocholic Acid 48-51 solute carrier family 10 member 1 Homo sapiens 0-4 34266968-12 2021 NTCP neutralizing antibody inhibited NTCP (less TCA uptake); it attenuated LF in both CCl4 and Ob/Ob HFD animal models with ameliorated metabolic profile. Taurocholic Acid 48-51 solute carrier family 10 member 1 Homo sapiens 37-41 33617845-11 2021 In marked contrast to the other E3S transporters, the bile acid transporter SLC10A1 (NTCP, Na+ taurocholate co-transporting polypeptide) showed a decrease in the accumulation of E3S in hyperosmolar buffer; the same was observed with taurocholic acid. Taurocholic Acid 233-249 solute carrier family 10 member 1 Homo sapiens 76-83 33617845-11 2021 In marked contrast to the other E3S transporters, the bile acid transporter SLC10A1 (NTCP, Na+ taurocholate co-transporting polypeptide) showed a decrease in the accumulation of E3S in hyperosmolar buffer; the same was observed with taurocholic acid. Taurocholic Acid 233-249 solute carrier family 10 member 1 Homo sapiens 85-89 33456536-3 2021 HBV-infected sodium taurocholate co-transporting polypeptide (NTCP)-transfected Huh7.5.1 cells were co-cultured with LX2 cells to simulate HBV infection in the present study. Taurocholic Acid 13-32 solute carrier family 10 member 1 Homo sapiens 62-66 32570893-3 2020 The identification of sodium taurocholate co-transporting polypeptide (NTCP) as an entry receptor for both HBV and its satellite virus hepatitis delta virus (HDV) has led to great advances in our understanding of the life cycle of HBV, including the early steps of infection in particular. Taurocholic Acid 22-41 solute carrier family 10 member 1 Homo sapiens 71-75 33445753-3 2021 Overexpression of the sodium taurocholate co-transporting polypeptide (NTCP) bile acid transporter in hepatoma cells improved infection efficiency. Taurocholic Acid 22-41 solute carrier family 10 member 1 Homo sapiens 71-75 33078647-6 2020 Compounds known to interact with NTCP, including chenodeoxycholic acid and taurocholic acid, displayed concentration-dependent inhibition of NTCP-mediated CDCA-NBD transport. Taurocholic Acid 75-91 solute carrier family 10 member 1 Homo sapiens 33-37 33078647-6 2020 Compounds known to interact with NTCP, including chenodeoxycholic acid and taurocholic acid, displayed concentration-dependent inhibition of NTCP-mediated CDCA-NBD transport. Taurocholic Acid 75-91 solute carrier family 10 member 1 Homo sapiens 141-145 32316189-7 2020 However, both stomatin overexpression and knockdown increased NTCP-mediated taurocholate uptake while NTCP abundance at the plasma membrane was only increased in stomatin depleted cells. Taurocholic Acid 76-88 solute carrier family 10 member 1 Homo sapiens 62-66 32568248-2 2020 Nonetheless, cell-based HBV models are limited to hepatoma cell lines (such as HepG2 and Huh7) overexpressing a functional HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP). Taurocholic Acid 137-156 solute carrier family 10 member 1 Homo sapiens 186-190 31485670-3 2019 The discovery of human sodium taurocholate co-transporting polypeptide (hNTCP) as a functional HBV receptor has enabled the development of a surrogate model to supplement the use of PHHs. Taurocholic Acid 23-42 solute carrier family 10 member 1 Homo sapiens 72-77 32101444-7 2020 Substrate-specific effects were observed for NTCP G191R, with TCA and rosuvastatin transport observed at 89% and 8% of wild type uptake, respectively. Taurocholic Acid 62-65 solute carrier family 10 member 1 Homo sapiens 45-49 31722821-1 2020 Sodium taurocholate cotransporting polypeptide (NTCP) involved in bile acid transport in the liver is an entry receptor of hepatitis B virus (HBV). Taurocholic Acid 0-19 solute carrier family 10 member 1 Homo sapiens 48-52 31722821-2 2020 In the present study, we introduce a mass spectrometric screening assay for targeting HBV entry inhibitors that can reduce NTCP transporter activity by employing taurocholic acid (TCA) labeled with stable isotope (2,2,4,4-d4-TCA, d4-TCA) and NTCP-overexpressing human liver cancer cell lines such as HepG2 and Huh-7. Taurocholic Acid 162-178 solute carrier family 10 member 1 Homo sapiens 123-127 31722821-2 2020 In the present study, we introduce a mass spectrometric screening assay for targeting HBV entry inhibitors that can reduce NTCP transporter activity by employing taurocholic acid (TCA) labeled with stable isotope (2,2,4,4-d4-TCA, d4-TCA) and NTCP-overexpressing human liver cancer cell lines such as HepG2 and Huh-7. Taurocholic Acid 162-178 solute carrier family 10 member 1 Homo sapiens 242-246 31722821-2 2020 In the present study, we introduce a mass spectrometric screening assay for targeting HBV entry inhibitors that can reduce NTCP transporter activity by employing taurocholic acid (TCA) labeled with stable isotope (2,2,4,4-d4-TCA, d4-TCA) and NTCP-overexpressing human liver cancer cell lines such as HepG2 and Huh-7. Taurocholic Acid 180-183 solute carrier family 10 member 1 Homo sapiens 123-127 31722821-2 2020 In the present study, we introduce a mass spectrometric screening assay for targeting HBV entry inhibitors that can reduce NTCP transporter activity by employing taurocholic acid (TCA) labeled with stable isotope (2,2,4,4-d4-TCA, d4-TCA) and NTCP-overexpressing human liver cancer cell lines such as HepG2 and Huh-7. Taurocholic Acid 225-228 solute carrier family 10 member 1 Homo sapiens 123-127 31722821-2 2020 In the present study, we introduce a mass spectrometric screening assay for targeting HBV entry inhibitors that can reduce NTCP transporter activity by employing taurocholic acid (TCA) labeled with stable isotope (2,2,4,4-d4-TCA, d4-TCA) and NTCP-overexpressing human liver cancer cell lines such as HepG2 and Huh-7. Taurocholic Acid 225-228 solute carrier family 10 member 1 Homo sapiens 123-127 31722821-4 2020 For the inhibitor screening assay, NTCP-overexpressing HepG2 or Huh-7 cells are treated with either a combination of TCA and an inhibitor (CsA or PreS/2-48Myr) or d4-TCA alone to serve as a reference. Taurocholic Acid 117-120 solute carrier family 10 member 1 Homo sapiens 35-39 31722821-4 2020 For the inhibitor screening assay, NTCP-overexpressing HepG2 or Huh-7 cells are treated with either a combination of TCA and an inhibitor (CsA or PreS/2-48Myr) or d4-TCA alone to serve as a reference. Taurocholic Acid 166-169 solute carrier family 10 member 1 Homo sapiens 35-39 30978651-3 2019 The herb-drug interactions that involve sodium taurocholate co-transporting polypeptide (NTCP) have been drawing increasing amounts of attention. Taurocholic Acid 40-59 solute carrier family 10 member 1 Homo sapiens 89-93 31018112-3 2019 Using infection systems encoding the HBV/HDV receptor human sodium taurocholate co-transporting polypeptide (NTCP), we screened 1181 FDA-approved drugs applying markers for interference for HBV and HDV infection. Taurocholic Acid 60-79 solute carrier family 10 member 1 Homo sapiens 109-113 32039379-13 2019 Lay summary: The experimental drug Myrcludex B binds the sodium taurocholate co-transporting polypeptide (NTCP), the viral entry receptor for the hepatitis B and D virus (HBV/HDV), and thereby prevents infection, but also inhibits hepatic bile salt uptake leading to transiently elevated bile salt levels. Taurocholic Acid 57-76 solute carrier family 10 member 1 Homo sapiens 106-110 31064734-3 2019 We examined the time-frame and host sites at which HBV integrates in HepG2 cells overexpressing sodium taurocholate co-transporting polypeptide (NTCP) receptor mediating HBV entry. Taurocholic Acid 96-115 solute carrier family 10 member 1 Homo sapiens 145-149 32039379-1 2019 Background & aims: The sodium taurocholate co-transporting polypeptide (NTCP) is the entry receptor for the hepatitis B and delta virus (HBV/HDV) and the main hepatic uptake transporter of conjugated bile acids. Taurocholic Acid 27-46 solute carrier family 10 member 1 Homo sapiens 76-80 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 169-185 solute carrier family 10 member 1 Homo sapiens 99-142 31117968-1 2019 BACKGROUND: Single nucleotide polymorphisms (SNPs) in the sodium taurocholate co-transporting polypeptide (NTCP) have been showed to be associated with natural history of hepatitis B virus (HBV) infection. Taurocholic Acid 58-77 solute carrier family 10 member 1 Homo sapiens 107-111 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 169-185 solute carrier family 10 member 1 Homo sapiens 144-148 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 187-190 solute carrier family 10 member 1 Homo sapiens 99-142 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 187-190 solute carrier family 10 member 1 Homo sapiens 144-148 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 263-266 solute carrier family 10 member 1 Homo sapiens 99-142 30639138-5 2019 In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA uptake was increased. Taurocholic Acid 263-266 solute carrier family 10 member 1 Homo sapiens 144-148 30556041-9 2018 Novel NTCP-interacting proteins were identified by mass spectrometry (MS), interaction verified, and assessed by co-immunoprecipitation and TCA uptake for functional relevance in relation to ER stress. Taurocholic Acid 140-143 solute carrier family 10 member 1 Homo sapiens 6-10 31258056-1 2019 BACKGROUND: Sodium Taurocholate Co-transporting Polypeptide (NTCP) and Bile Salt Export Pump (BSEP) play significant roles as membrane transporters because of their presence in the enterohepatic circulation of bile salts. Taurocholic Acid 12-31 solute carrier family 10 member 1 Homo sapiens 61-65 30032030-3 2018 The p.Ser267Phe (S267F) variant of NTCP is a single nucleotide polymorphism (SNP) previously found to cause substantial loss of ability to support HBV and HDV infection and its taurocholic acid uptake function in vitro. Taurocholic Acid 177-193 solute carrier family 10 member 1 Homo sapiens 35-39 29805766-5 2018 We also found that glabridin could attenuate the inhibitory effect of taurocholate on type I interferon signaling by depleting the level of cell-surface NTCP. Taurocholic Acid 70-82 solute carrier family 10 member 1 Homo sapiens 153-157 27251172-2 2016 HBV enters hepatocytes by binding to sodium taurocholate cotransporting polypeptide (NTCP), the genome of which contains 2 active farnesoid X receptor (FXR) alpha response elements that participate in HBV transcriptional activity. Taurocholic Acid 37-56 solute carrier family 10 member 1 Homo sapiens 85-89 28962642-6 2017 Pre-treatment of D-UCMSCs with taurocholate, a specific NTCP substrate, blocked their infection by HBV which supports the crucial involvement of this transporter in the early steps of the virus entry. Taurocholic Acid 31-43 solute carrier family 10 member 1 Homo sapiens 56-60 27676153-4 2016 Fusidic acid demonstrated concentration-dependent inhibition of human NTCP- and BSEP-mediated taurocholic acid transport with IC50 values of 44 and 3.8 muM, respectively. Taurocholic Acid 94-110 solute carrier family 10 member 1 Homo sapiens 70-74 29212823-7 2018 OCT1- and NTCP-mediated uptake of N-methyl-4-phenylpyridinium acetate and taurocholate was demonstrated in both hepatic models, whereas active uptake of OATP1B1/1B3-selective marker substrates, paralleled by markedly reduced SLCO1B1/1B3 expression, were not detectable in SCUHH. Taurocholic Acid 74-86 solute carrier family 10 member 1 Homo sapiens 10-14 27784961-2 2016 Then, it is promptly transferred to the sodium taurocholate cotransporting polypeptide (NTCP) via the myristoylated N-terminal sequence of pre-S1 region (from Gly-2 to Gly-48, HBV genotype D), and it finally enters the cell by endocytosis. Taurocholic Acid 40-59 solute carrier family 10 member 1 Homo sapiens 88-92 25765005-7 2015 In parallel, we observed a 98% decrease in NTCP mRNA steady state level and an 80% reduction in NTCP-mediated taurocholate uptake. Taurocholic Acid 110-122 solute carrier family 10 member 1 Homo sapiens 96-100 25765005-8 2015 IL-6-mediated inhibition of NTCP-mediated taurocholate uptake and viral entry exhibited similar dose-dependence and kinetics while restoration of NTCP expression suppressed the inhibitory effect of IL-6. Taurocholic Acid 42-54 solute carrier family 10 member 1 Homo sapiens 28-32 25168282-3 2014 First, we evaluated the uptake of taurocholate (TCA) by hNTCP heterologously expressed in Xenopus oocytes utilizing [(3)H]-labeled TCA. Taurocholic Acid 34-46 solute carrier family 10 member 1 Homo sapiens 56-61 25690737-6 2015 Contrary to other transporters, NTCP and BSEP were less abundant and active in HepaRG cells, cellular uptake of taurocholate was 2.2- and 1.4-fold and bile excretion index 2.8- and 2.6-fold lower, than in SCHHs and CCHHs, respectively. Taurocholic Acid 112-124 solute carrier family 10 member 1 Homo sapiens 32-36 25929767-2 2015 Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention. Taurocholic Acid 101-120 solute carrier family 10 member 1 Homo sapiens 150-154 25168282-8 2014 The transport of TCA via hNTCP was subsequently determined in the oocytes by the inward currents induced via TCA uptake under voltage (-50 mV). Taurocholic Acid 17-20 solute carrier family 10 member 1 Homo sapiens 25-30 25168282-8 2014 The transport of TCA via hNTCP was subsequently determined in the oocytes by the inward currents induced via TCA uptake under voltage (-50 mV). Taurocholic Acid 109-112 solute carrier family 10 member 1 Homo sapiens 25-30 25168282-3 2014 First, we evaluated the uptake of taurocholate (TCA) by hNTCP heterologously expressed in Xenopus oocytes utilizing [(3)H]-labeled TCA. Taurocholic Acid 48-51 solute carrier family 10 member 1 Homo sapiens 56-61 25168282-3 2014 First, we evaluated the uptake of taurocholate (TCA) by hNTCP heterologously expressed in Xenopus oocytes utilizing [(3)H]-labeled TCA. Taurocholic Acid 131-134 solute carrier family 10 member 1 Homo sapiens 56-61 25168282-4 2014 The uptake of 1.2 muM TCA by cRNA-injected oocytes increased more than 100-fold compared to H2O-injected oocytes, indicating that hNTCP is robustly expressed in the oocytes. Taurocholic Acid 22-25 solute carrier family 10 member 1 Homo sapiens 130-135 25168282-5 2014 hNTCP-mediated transport of TCA is saturable with a Michaelis constant of 10.5 +- 2.9 muM. Taurocholic Acid 28-31 solute carrier family 10 member 1 Homo sapiens 0-5 25168282-6 2014 The Na(+)-activation kinetics describing the relationship between the concentration of Na(+) and the magnitude of the TCA uptake rate by hNTCP were sigmoidal with a Hill coefficient of 2.3 +- 0.4, indicating the involvement of more than one Na(+) in the transport process. Taurocholic Acid 118-121 solute carrier family 10 member 1 Homo sapiens 137-142 24768844-6 2014 The myristoylated N-terminal preS1 domain of the L protein subsequently binds to the sodium taurocholate cotransporting polypeptide (NTCP, encoded by SLC10A1), the recently identified bona fide receptor for HBV and HDV. Taurocholic Acid 85-104 solute carrier family 10 member 1 Homo sapiens 133-137 24965018-0 2014 In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Taurocholic Acid 90-109 solute carrier family 10 member 1 Homo sapiens 139-143 24965018-1 2014 OBJECTIVES: The aim of this study was to explore sodium taurocholate co-transporting polypeptide (NTCP) exerting its function with hepatitis B virus (HBV) and its targeted candidate compounds, in HBV therapy. Taurocholic Acid 49-68 solute carrier family 10 member 1 Homo sapiens 98-102 24390325-4 2014 Here we show that binding of the pre-S1 domain to human NTCP blocks taurocholate uptake by the receptor; conversely, some bile acid substrates of NTCP inhibit HBV and HDV entry. Taurocholic Acid 68-80 solute carrier family 10 member 1 Homo sapiens 56-60 24754247-8 2014 Proscillaridin A was the most effective inhibitor of NTCP-mediated TCA transport (IC50 = 22 muM), whereas digitoxin and digitoxigenin were the most potent inhibitors of OATP1B1 and OAPTP1B3, with IC50 values of 14.2 and 36 muM, respectively. Taurocholic Acid 67-70 solute carrier family 10 member 1 Homo sapiens 53-57 24375637-5 2014 Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP). Taurocholic Acid 101-120 solute carrier family 10 member 1 Homo sapiens 149-153 24295872-2 2014 The myristoylated preS1 domain of the large envelope protein mediates specific binding to hepatocytes by sodium taurocholate co-transporting polypeptide (NTCP). Taurocholic Acid 105-124 solute carrier family 10 member 1 Homo sapiens 154-158 22641618-7 2012 Six out of 10 structurally diverse compounds selected in the first virtual screening procedure significantly inhibited taurocholate uptake in the NTCP overexpressing cells. Taurocholic Acid 119-131 solute carrier family 10 member 1 Homo sapiens 146-150 23886862-7 2013 We speculated that NO would target C266 since a previous report had shown the thiol reactive compound [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET) inhibits TC uptake by wild-type NTCP but not by C266A NTCP. Taurocholic Acid 178-180 solute carrier family 10 member 1 Homo sapiens 201-205 23886862-7 2013 We speculated that NO would target C266 since a previous report had shown the thiol reactive compound [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET) inhibits TC uptake by wild-type NTCP but not by C266A NTCP. Taurocholic Acid 178-180 solute carrier family 10 member 1 Homo sapiens 223-227 22897388-7 2012 We observed saturable uptake of typical substrates of NTCP and OATPs except for cholecystokinin octapeptide (OATP1B3-selective substrate), and Na(+)-dependent uptake of taurocholate was confirmed. Taurocholic Acid 169-181 solute carrier family 10 member 1 Homo sapiens 54-58 23886862-0 2013 Cysteine 96 of Ntcp is responsible for NO-mediated inhibition of taurocholate uptake. Taurocholic Acid 65-77 solute carrier family 10 member 1 Homo sapiens 15-19 23886862-1 2013 The Na(+) taurocholate (TC) cotransporting polypeptide Ntcp/NTCP mediates TC uptake across the sinusoidal membrane of hepatocytes. Taurocholic Acid 24-26 solute carrier family 10 member 1 Homo sapiens 55-59 23886862-1 2013 The Na(+) taurocholate (TC) cotransporting polypeptide Ntcp/NTCP mediates TC uptake across the sinusoidal membrane of hepatocytes. Taurocholic Acid 24-26 solute carrier family 10 member 1 Homo sapiens 60-64 23886862-1 2013 The Na(+) taurocholate (TC) cotransporting polypeptide Ntcp/NTCP mediates TC uptake across the sinusoidal membrane of hepatocytes. Taurocholic Acid 61-63 solute carrier family 10 member 1 Homo sapiens 55-59 23886862-3 2013 Our current aim was to determine which of the eight cysteine residues of Ntcp is responsible for NO-mediated S-nitrosylation and inhibition of TC uptake. Taurocholic Acid 143-145 solute carrier family 10 member 1 Homo sapiens 73-77 23886862-5 2013 Of the eight mutants tested, only C44A Ntcp displayed decreased total and plasma membrane (PM) levels that were also reflected in decreased TC uptake. Taurocholic Acid 140-142 solute carrier family 10 member 1 Homo sapiens 39-43 23886862-6 2013 C266A Ntcp showed a decrease in TC uptake that was not explained by a decrease in total expression or PM localization, indicating that C266 is required for optimal uptake. Taurocholic Acid 32-34 solute carrier family 10 member 1 Homo sapiens 6-10 21945488-4 2011 Chinese Hamster Ovary cells transfected with human NTCP (CHO-NTCP) were used to investigate the inhibitory effect of fluvastatin and other statins on [(3)H]-taurocholic acid uptake ([(3)H]-TCA). Taurocholic Acid 157-173 solute carrier family 10 member 1 Homo sapiens 57-65 22029531-13 2012 Expression of SLC10A4 and NTCP Y307X resulted in a reduction of NTCP abundance at the plasma membrane and NTCP-mediated taurocholate uptake, whereas expression of SLC10A6 or NTCP E257N, an inactive mutant, did not affect NTCP function. Taurocholic Acid 120-132 solute carrier family 10 member 1 Homo sapiens 26-30 21109590-0 2011 Nitric oxide-mediated inhibition of taurocholate uptake involves S-nitrosylation of NTCP. Taurocholic Acid 36-48 solute carrier family 10 member 1 Homo sapiens 84-88 21605667-4 2011 In CHHS, the mean accumulation clearance of the NTCP substrate taurocholate (1 muM) was 27.5 (+-15.0) mul/min/million cells and decreased by 10-fold when extracellular sodium was replaced by choline. Taurocholic Acid 63-75 solute carrier family 10 member 1 Homo sapiens 48-52 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Taurocholic Acid 83-95 solute carrier family 10 member 1 Homo sapiens 23-27 21341987-5 2011 The stably transfected NTCP-A64T variant showed significantly decreased uptakes of taurocholate and rosuvastatin compared with wild-type NTCP. Taurocholic Acid 83-95 solute carrier family 10 member 1 Homo sapiens 137-141 21341987-6 2011 The decreased taurocholate uptake and increased rosuvastatin uptake were shown in the NTCP-S267F variant. Taurocholic Acid 14-26 solute carrier family 10 member 1 Homo sapiens 86-90 21109590-1 2011 The sodium-taurocholate (TC) cotransporting polypeptide (NTCP) facilitates bile formation by mediating sinusoidal Na(+)-TC cotransport. Taurocholic Acid 4-23 solute carrier family 10 member 1 Homo sapiens 57-61 21109590-1 2011 The sodium-taurocholate (TC) cotransporting polypeptide (NTCP) facilitates bile formation by mediating sinusoidal Na(+)-TC cotransport. Taurocholic Acid 25-27 solute carrier family 10 member 1 Homo sapiens 57-61 21109590-5 2011 Using a human hepatoma cell line stably expressing NTCP (HuH-NTCP), we performed experiments with the NO donors sodium nitroprusside and S-nitrosocysteine and demonstrated that NO inhibits TC uptake in these cells. Taurocholic Acid 52-54 solute carrier family 10 member 1 Homo sapiens 57-65 21109590-12 2011 Taken together these results indicate that the inhibition of TC uptake by NO involves S-nitrosylation of NTCP. Taurocholic Acid 61-63 solute carrier family 10 member 1 Homo sapiens 105-109 20177056-8 2010 In conclusion, pregnancy levels of P4-S can inhibit Na(+)-dependent and -independent influx of taurocholate in PHH and cause competitive inhibition of NTCP-mediated uptake of taurocholate in Xenopus oocytes. Taurocholic Acid 175-187 solute carrier family 10 member 1 Homo sapiens 151-155 21103971-5 2011 Uptake of bile salts into hepatocytes occurs largely in a sodium-dependent manner by the sodium taurocholate cotransporting polypeptide NTCP. Taurocholic Acid 89-108 solute carrier family 10 member 1 Homo sapiens 136-140 20946088-2 2011 The functional activities and simultaneous expression of NTCP and OATP1B1 were confirmed by the uptake of taurocholate and estrone-3-sulphate as representative substrates for NTCP and OATP1B1, respectively, and by an immunofluorescence analysis. Taurocholic Acid 106-118 solute carrier family 10 member 1 Homo sapiens 57-61 20946088-2 2011 The functional activities and simultaneous expression of NTCP and OATP1B1 were confirmed by the uptake of taurocholate and estrone-3-sulphate as representative substrates for NTCP and OATP1B1, respectively, and by an immunofluorescence analysis. Taurocholic Acid 106-118 solute carrier family 10 member 1 Homo sapiens 175-179 18328802-5 2008 Expression, localization and function of Ntcp in these cells were assessed by immunoblotting, immunofluorescence and biotinylation studies and Na+ -dependent taurocholate uptake assays, respectively. Taurocholic Acid 158-170 solute carrier family 10 member 1 Homo sapiens 41-45 19682536-5 2010 The SLC10A1 substrates taurocholate, DHEAS and E3S inhibit T3S and T4S transport. Taurocholic Acid 23-35 solute carrier family 10 member 1 Homo sapiens 4-11 18688880-1 2008 UNLABELLED: Cyclic adenosine monophosphate (cAMP) stimulates hepatic bile acid uptake by translocating sodium-taurocholate (TC) cotransporting polypeptide (Ntcp) from an endosomal compartment to the plasma membrane. Taurocholic Acid 103-122 solute carrier family 10 member 1 Homo sapiens 156-160 18688880-1 2008 UNLABELLED: Cyclic adenosine monophosphate (cAMP) stimulates hepatic bile acid uptake by translocating sodium-taurocholate (TC) cotransporting polypeptide (Ntcp) from an endosomal compartment to the plasma membrane. Taurocholic Acid 124-126 solute carrier family 10 member 1 Homo sapiens 156-160 17991769-5 2008 It concomitantly reduced NTCP protein levels and NTCP-mediated cellular uptake of taurocholate in HepaRG cells. Taurocholic Acid 82-94 solute carrier family 10 member 1 Homo sapiens 49-53 16760228-6 2006 The aminofluorescein-tagged bile acids, chenodeoxycholylglycylamidofluorescein and cholylglycylamidofluorescein, were substrates of both NTCP and BSEP, and their basal-to-apical transport rates across coexpressing cell monolayers were 4.3 to 4.5 times those of the vector control, although smaller than for taurocholate. Taurocholic Acid 307-319 solute carrier family 10 member 1 Homo sapiens 137-141 18418673-8 2008 Several classes of transporters, organic anion transporter polypeptide (oatp) family, Na(+)/Taurocholate cotransporting polypeptide (ntcp) and amino acid transporters have been reported to transport thyroid hormones. Taurocholic Acid 92-104 solute carrier family 10 member 1 Homo sapiens 133-137 16760228-7 2006 The well known cholestatic drugs, rifampicin, rifamycin SV, glibenclamide, and cyclosporin A, reduced the basal-to-apical transport and the apical efflux clearance of taurocholate across NTCP- and BSEP-coexpressing cell monolayers. Taurocholic Acid 167-179 solute carrier family 10 member 1 Homo sapiens 187-191 12034724-6 2002 TC uptake in HuH-Ntcp cells was more than 90% dependent on extracellular Na+. Taurocholic Acid 0-2 solute carrier family 10 member 1 Homo sapiens 17-21 12510858-5 2002 On the contrary, the uptake of taurocholate was significantly inhibited by the pretreatment, resulting in a significant decrease in Vmax, thus providing a clear demonstration that NOx preferentially affects the function of NTCP rather than OCT on the sinusoidal membrane. Taurocholic Acid 31-43 solute carrier family 10 member 1 Homo sapiens 223-227 8132774-6 1994 Saturation kinetics indicated that the human NTCP has a higher affinity for taurocholate (apparent Km = 6 microM) than the previously cloned rat protein (apparent Km = 25 microM). Taurocholic Acid 76-88 solute carrier family 10 member 1 Homo sapiens 45-49 11352825-3 2001 Taurocholate uptake studies and confocal microscopy demonstrated that the polarity of basolateral surface expression of NTCP-GFP was maintained in MDCK cells but was lost in Caco-2 cells. Taurocholic Acid 0-12 solute carrier family 10 member 1 Homo sapiens 120-124 10565843-7 1999 Expressed NTCP exhibited high-affinity, sodium-dependent uptake of taurocholate, and as expected, this was markedly inhibited by bile acids and organic anions. Taurocholic Acid 67-79 solute carrier family 10 member 1 Homo sapiens 10-14 9425937-8 1998 Western blots immunostained for the basolateral Na+-dependent plasma membrane protein, ntcp, revealed the appropriate approximately 50-kd band in control and TC-grown cells, and confocal immunofluorescence microscopy demonstrated staining along the basolateral plasma membrane. Taurocholic Acid 158-160 solute carrier family 10 member 1 Homo sapiens 87-91 9425937-9 1998 Northern blots hybridized with a cDNA probe directed against ntcp indicated a modest TC-induced increase in mRNA levels. Taurocholic Acid 85-87 solute carrier family 10 member 1 Homo sapiens 61-65 12059989-8 2002 RESULTS: [(3)H]taurocholic acid uptake was approximately 180-fold higher in Ntcp-transfected than in sham-transfected cells. Taurocholic Acid 15-31 solute carrier family 10 member 1 Homo sapiens 76-80 8132774-7 1994 NTCP-mediated taurocholate uptake into oocytes was inhibited by all major bile acid derivatives (100 microM), bumetanide (500 microM), and bromosulphophthalein (100 microM). Taurocholic Acid 14-26 solute carrier family 10 member 1 Homo sapiens 0-4 33807170-1 2021 The discovery of sodium taurocholate co-transporting polypeptide (NTCP) as a hepatitis B (HBV) and delta virus (HDV) entry receptor has encouraged the development of new animal models of infection. Taurocholic Acid 17-36 solute carrier family 10 member 1 Homo sapiens 66-70 33782042-1 2021 Bile salts such as cholate, glycocholate, taurocholate and glycochenodeoxycholate are taken up from the portal blood into hepatocytes via transporters such as the Na+-taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs). Taurocholic Acid 42-54 solute carrier family 10 member 1 Homo sapiens 163-206 33782042-1 2021 Bile salts such as cholate, glycocholate, taurocholate and glycochenodeoxycholate are taken up from the portal blood into hepatocytes via transporters such as the Na+-taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides (OATPs). Taurocholic Acid 42-54 solute carrier family 10 member 1 Homo sapiens 208-212 34794962-10 2022 The increase in NTCP protein abundance correlated with increased function; dasatinib and pazopanib increased hepatocyte uptake clearance (CLuptake) of taurocholic acid, a probe bile acid substrate, up to 1.4 fold. Taurocholic Acid 151-167 solute carrier family 10 member 1 Homo sapiens 16-20